Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SODIUM DITIOCARB AS ADJUVANT IMMUNOTHERAPY FOR HIGH-RISK BREAST-CANCER - A RANDOMIZED STUDY
Autore:
DUFOUR P; LANG JM; GIRON C; DUCLOS B; HAEHNEL P; JAECK D; JUNG JM; OBERLING F;
Indirizzi:
CHU HAUTEPIERRE,SERV ONCOHEMATOL F-67098 STRASBOURG FRANCE CTR RADIOL F-67000 STRASBOURG FRANCE CHU HAUTEPIERRE,SERV CHIRURG DIGEST F-67098 STRASBOURG FRANCE CTR PAUL STRAUSS F-67000 STRASBOURG FRANCE
Titolo Testata:
Biotherapy
fascicolo: 1, volume: 6, anno: 1993,
pagine: 9 - 12
SICI:
0921-299X(1993)6:1<9:SDAAIF>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOUBLE-BLIND; DIETHYLDITHIOCARBAMATE; LEVAMISOLE; INFECTION; THERAPY;
Keywords:
ADJUVANT IMMUNOTHERAPY; BREAST CANCER; DITIOCARB SODIUM;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
19
Recensione:
Indirizzi per estratti:
Citazione:
P. Dufour et al., "SODIUM DITIOCARB AS ADJUVANT IMMUNOTHERAPY FOR HIGH-RISK BREAST-CANCER - A RANDOMIZED STUDY", Biotherapy, 6(1), 1993, pp. 9-12

Abstract

Sixty-four patients with non metastatic high risk breast cancer were randomized in a double blind trial of adjuvant immunotherapy with sodium ditiocarb (DDC) versus placebo. All patients underwent prior surgery (mammectomy according to Patey) then adjuvant FAC chemotherapy +/- DDC. With a median follow-up of 5 years we observed 6 relapses and 5 deaths in DDC group; 13 relapses and t2 deaths in control group. At 6 years, overall survival is 81% in DDC group versus 55%. Disease free survival (DFS) is 76% in DDC group versus 55%. DDC associated to chemotherapy and locoregional treatment can improve survival and probably DFS in this high risk breast cancer subgroup.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 17:13:34